PTGIR
ENSG00000160013
Target class
GPCR
Chromosome
19
Approved drugs
7
Clinical candidates (approved and in development)
9
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- Yes
- Other names
- IP
- Target name
- PTGIR
- Gene name
- Prostaglandin I2 receptor
- Gene symbol
- PTGIR
- Protein name
- Prostacyclin receptor (Prostaglandin I2 receptor) (PGI receptor) (PGI2 receptor) (Prostanoid IP receptor)
- Gene biotype
- Protein coding
- Gene family
- Prostaglandin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 40
- Highest tissue expression
- 111.94
- Tissue specificity (Gini)
- 0.675
- Tissue specificity (tau)
- 0.929
- KEGG gene identifiers
- hsa:5739
- Protein interaction confidence
- 0.85025
- Protein interaction partners
- 4
- R-HSA-391908
- R-HSA-392851
- R-HSA-418555
- End position
- 46625534
- Start position
- 46618550
- Chromosome
- 19
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.929435
- Expression inequality (Gini)
- 0.674692
Expression in transcripts per million
- Artery - Aorta
- 111.94
- Lung
- 55.86
- Artery - Coronary
- 55.18
- Artery - Tibial
- 38.86
- Thyroid
- 25.83
Expression in transcripts per million
- Artery - Aorta111.94
- Lung55.86
- Artery - Coronary55.18
- Artery - Tibial38.86
- Thyroid25.83
- Cells - Cultured fibroblasts18.55
- Heart - Atrial Appendage18.4
- Adipose - Visceral (Omentum)15.35
- Cells - EBV-transformed lymphocytes13.22
- Spleen11.27
- Kidney - Medulla10.47
- Fallopian Tube9.87
- Kidney - Cortex9.76
- Adipose - Subcutaneous9.26
- Cervix - Ectocervix9.09
- Nerve - Tibial8.29
- Esophagus - Gastroesophageal Junction7.25
- Cervix - Endocervix6.64
- Vagina6.6
- Adrenal Gland6.46
- Esophagus - Muscularis6.4
- Small Intestine - Terminal Ileum6.04
- Uterus5.85
- Colon - Sigmoid5.46
- Breast - Mammary Tissue5.21
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007189
- GO:0007267
- GO:0048662
- GO:0005829
- GO:0005886
- GO:0005085
- GO:0005515
Related records
Trials (299)
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
- A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
- A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
- A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
- A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment
- A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
- A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
- A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
- A Study of Ralinepag in Healthy Chinese Adult Subjects
Drugs (17)
- Alprostadil
- Beraprost
- Cicaprost
- Epoprostenol Prostanoid IP receptor agonist
- Epoprostenol sodium Prostanoid IP receptor agonist
- Esuberaprost Prostanoid IP receptor agonist
- Esuberaprost potassium Prostanoid IP receptor agonist
- Esuberaprost sodium Prostanoid IP receptor agonist
- Iloprost Prostanoid IP receptor agonist
- Iloprost tromethamine Prostanoid IP receptor agonist
- Laselipag
- Ralinepag Prostanoid IP receptor agonist
- Selexipag Prostanoid IP receptor agonist
- Taprostene
- Treprostinil Prostanoid IP receptor agonist
- Treprostinil diolamine Prostanoid IP receptor agonist
- Treprostinil sodium Prostanoid IP receptor agonist